JP6628719B2 - 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 - Google Patents

抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 Download PDF

Info

Publication number
JP6628719B2
JP6628719B2 JP2016527006A JP2016527006A JP6628719B2 JP 6628719 B2 JP6628719 B2 JP 6628719B2 JP 2016527006 A JP2016527006 A JP 2016527006A JP 2016527006 A JP2016527006 A JP 2016527006A JP 6628719 B2 JP6628719 B2 JP 6628719B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tcr
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016527230A5 (enExample
JP2016527230A (ja
Inventor
エス． ヒンリクス、クリスチャン
エス． ヒンリクス、クリスチャン
エイ． ローゼンバーグ、スティーヴン
エイ． ローゼンバーグ、スティーヴン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2016527230A publication Critical patent/JP2016527230A/ja
Publication of JP2016527230A5 publication Critical patent/JP2016527230A5/ja
Priority to JP2019219105A priority Critical patent/JP6959970B2/ja
Application granted granted Critical
Publication of JP6628719B2 publication Critical patent/JP6628719B2/ja
Priority to JP2021166407A priority patent/JP7223822B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016527006A 2013-07-15 2014-07-14 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 Active JP6628719B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019219105A JP6959970B2 (ja) 2013-07-15 2019-12-03 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2021166407A JP7223822B2 (ja) 2013-07-15 2021-10-08 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846167P 2013-07-15 2013-07-15
US61/846,167 2013-07-15
PCT/US2014/046480 WO2015009606A1 (en) 2013-07-15 2014-07-14 Anti-human papillomavirus 16 e6 t cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019219105A Division JP6959970B2 (ja) 2013-07-15 2019-12-03 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2016527230A JP2016527230A (ja) 2016-09-08
JP2016527230A5 JP2016527230A5 (enExample) 2017-08-17
JP6628719B2 true JP6628719B2 (ja) 2020-01-15

Family

ID=51298958

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016527006A Active JP6628719B2 (ja) 2013-07-15 2014-07-14 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2019219105A Active JP6959970B2 (ja) 2013-07-15 2019-12-03 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2021166407A Active JP7223822B2 (ja) 2013-07-15 2021-10-08 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019219105A Active JP6959970B2 (ja) 2013-07-15 2019-12-03 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
JP2021166407A Active JP7223822B2 (ja) 2013-07-15 2021-10-08 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体

Country Status (8)

Country Link
US (5) US9822162B2 (enExample)
EP (2) EP3022223B1 (enExample)
JP (3) JP6628719B2 (enExample)
CN (2) CN110511960B (enExample)
AU (1) AU2014290288B2 (enExample)
CA (1) CA2918216C (enExample)
ES (2) ES2745472T3 (enExample)
WO (1) WO2015009606A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3149031T3 (da) 2014-05-29 2020-03-16 Us Health Anti-human papillomavirus 16 e7 t-cellereceptorer
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
EP3356396A1 (en) * 2015-10-01 2018-08-08 Ospedale San Raffaele S.r.l. Tcr and uses thereof
CN114195882A (zh) 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
EP3156067A1 (en) 2015-10-16 2017-04-19 Max-Delbrück-Centrum Für Molekulare Medizin High avidity hpv t-cell receptors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
PL3430037T3 (pl) * 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
US11352410B2 (en) 2016-04-26 2022-06-07 The United States of American, as represented by the Secretary, Department of Health and Human Service Anti-KK-LC-1 T cell receptors
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
EP3519433A1 (en) * 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN110914295B (zh) 2017-06-28 2024-08-09 里珍纳龙药品有限公司 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法
DE102017114737A1 (de) * 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
EP3692063A1 (en) 2017-10-03 2020-08-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3077595A1 (en) * 2017-10-05 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing, monitoring and treating neurological diseases and disorders
KR20200063215A (ko) 2017-10-06 2020-06-04 오슬로 유니버시테시케후스 에이치에프 키메라 항원 수용체
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
CN118374524A (zh) 2018-02-09 2024-07-23 美国卫生和人力服务部 拴系白细胞介素-15和白细胞介素-21
MA52003A (fr) * 2018-03-12 2021-01-20 Sqz Biotechnologies Co Procédés de traitement de maladies associées au hpv
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CN112262212B (zh) 2018-04-24 2024-07-12 美国卫生和人力服务部 使用羟基柠檬酸和/或其盐产生t细胞群体的方法
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
CN113272435B (zh) * 2018-09-05 2025-11-14 加利福尼亚大学董事会 在多个主要组织相容性复合体分子上受限的ny-eso-1特异性t细胞受体的组合物
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
WO2020191365A1 (en) 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
WO2020227091A1 (en) * 2019-05-03 2020-11-12 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
WO2021155518A1 (en) * 2020-02-05 2021-08-12 Tcrcure Biopharma Corp Anti-hpv t cell receptors and engineered cells
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research COMPOSITIONS AND METHODS FOR TARGETING HPV-INFECTED CELLS
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022104035A2 (en) 2020-11-13 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN114539385A (zh) * 2020-11-26 2022-05-27 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的tcr
CN112480239B (zh) * 2020-12-02 2022-06-07 中国科学院微生物研究所 人乳头瘤病毒特异性t细胞受体及其抗肿瘤用途
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4384543A4 (en) * 2021-09-07 2025-06-11 Corregene Biotechnology Co., Ltd. ANTIGEN-BINDING PROTEINS AND USES THEREOF
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
IL316032A (en) 2022-04-08 2024-11-01 Regeneron Pharma Multicomponent receptor and signaling complexes
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
CN118108854B (zh) * 2024-03-26 2024-07-19 广西福莱明生物制药有限公司 一种含有双特异性抗体的抗病毒组合物及其应用
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2205138A1 (en) 1994-11-16 1996-05-23 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2007013092A1 (en) * 2005-07-25 2007-02-01 Trinity Future-In Pvt. Ltd An electro-mechanical system for non-duplication of video files
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
AU2008206442B2 (en) * 2007-01-12 2012-10-18 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services gp100-specific T cell receptors and related materials and methods of use
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
CN103124740B (zh) * 2010-09-21 2015-09-02 美国卫生和人力服务部 抗-ssx-2t细胞受体和相关材料及使用方法
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers

Also Published As

Publication number Publication date
US20190309043A1 (en) 2019-10-10
CA2918216C (en) 2023-03-21
CN105452288B (zh) 2019-08-13
ES2973064T3 (es) 2024-06-18
US20160152681A1 (en) 2016-06-02
JP2020054359A (ja) 2020-04-09
US20210130433A1 (en) 2021-05-06
US12187779B2 (en) 2025-01-07
EP3572423B1 (en) 2023-12-06
JP6959970B2 (ja) 2021-11-05
EP3572423A1 (en) 2019-11-27
JP2016527230A (ja) 2016-09-08
US10913785B2 (en) 2021-02-09
WO2015009606A1 (en) 2015-01-22
US20230340066A1 (en) 2023-10-26
AU2014290288A1 (en) 2016-02-04
JP7223822B2 (ja) 2023-02-16
ES2745472T3 (es) 2020-03-02
EP3022223A1 (en) 2016-05-25
US10329339B2 (en) 2019-06-25
CN110511960A (zh) 2019-11-29
JP2022017292A (ja) 2022-01-25
EP3022223B1 (en) 2019-06-19
CN105452288A (zh) 2016-03-30
CA2918216A1 (en) 2015-01-22
US11697676B2 (en) 2023-07-11
US9822162B2 (en) 2017-11-21
AU2014290288B2 (en) 2018-03-01
US20180094041A1 (en) 2018-04-05
CN110511960B (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
US12187779B2 (en) Anti-human papillomavirus 16 E6 T cell receptors
US12534508B2 (en) Anti-human papillomavirus 16 E7 T cell receptors
EP3223850B1 (en) Anti-mutated kras t cell receptors
HK40018191A (en) Anti-human papillomavirus 16 e6 t cell receptors
HK40031837A (en) Anti-mutated kras t cell receptors
HK40030123B (en) Expression vectors for anti-human papillomavirus 16 e7 t cell receptors
HK40018191B (en) Anti-human papillomavirus 16 e6 t cell receptors
HK40030123A (en) Expression vectors for anti-human papillomavirus 16 e7 t cell receptors
HK1243642B (en) Anti-mutated kras t cell receptors
HK1236203A1 (en) Anti-human papillomavirus 16 e7 t cell receptors
HK1236203B (en) Anti-human papillomavirus 16 e7 t cell receptors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191203

R150 Certificate of patent or registration of utility model

Ref document number: 6628719

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250